Non-alcoholic Fatty Liver Disease in Children.

IF 2.8 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Current vascular pharmacology Pub Date : 2023-01-01 DOI:10.2174/1570161121666221118155136
Emir Muzurović, Stergios Polyzos, Dimitri Mikhailidis, Sanja Borozan, Dušanka Novosel, Oleg Cmiljanić, Nataša Kadić, Christos Mantzoros
{"title":"Non-alcoholic Fatty Liver Disease in Children.","authors":"Emir Muzurović,&nbsp;Stergios Polyzos,&nbsp;Dimitri Mikhailidis,&nbsp;Sanja Borozan,&nbsp;Dušanka Novosel,&nbsp;Oleg Cmiljanić,&nbsp;Nataša Kadić,&nbsp;Christos Mantzoros","doi":"10.2174/1570161121666221118155136","DOIUrl":null,"url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the paediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis (NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes mellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity and mortality, the latter being related mostly due to cardiovascular disease and malignancies. This narrative review, which included 236 articles, summarizes current evidence on paediatric NAFLD, including pathophysiology, risk factors, complications, prevention and treatment (existing and emerging). Early recognition of NAFLD followed by timely and adequate management seems to be important on an individual basis. A global \"call to action\" regarding paediatric NAFLD seems appropriate to mitigate the burden of this disease.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1570161121666221118155136","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 5

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the paediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis (NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes mellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity and mortality, the latter being related mostly due to cardiovascular disease and malignancies. This narrative review, which included 236 articles, summarizes current evidence on paediatric NAFLD, including pathophysiology, risk factors, complications, prevention and treatment (existing and emerging). Early recognition of NAFLD followed by timely and adequate management seems to be important on an individual basis. A global "call to action" regarding paediatric NAFLD seems appropriate to mitigate the burden of this disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿童非酒精性脂肪性肝病
非酒精性脂肪性肝病(NAFLD)已成为儿科最常见的肝脏疾病。在儿童和青少年中,NAFLD及其晚期表型非酒精性脂肪性肝炎(NASH)的流行率不断上升,与肥胖和2型糖尿病的流行趋势相似。这一趋势可能产生严重的长期影响,包括肝脏和肝外的发病率和死亡率,后者主要与心血管疾病和恶性肿瘤有关。这篇叙述性综述包括236篇文章,总结了目前关于儿科NAFLD的证据,包括病理生理学、危险因素、并发症、预防和治疗(现有和新出现的)。对NAFLD的早期识别以及及时和适当的治疗似乎对个人很重要。针对儿科NAFLD的全球“行动呼吁”似乎是适当的,以减轻这种疾病的负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current vascular pharmacology
Current vascular pharmacology 医学-外周血管病
CiteScore
9.20
自引率
4.40%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research. Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).
期刊最新文献
Rare Endocrine Disorders and Peripheral Arterial Disease. Where to Next after BASIL-2 and BEST-CLI? Current Strategies for Atrial Fibrillation Prevention and Management: Taming the Commonest Cardiac Arrhythmia. Delineating the NOX-Mediated Promising Therapeutic Strategies for the Management of Various Cardiovascular Disorders: A Comprehensive Review. Comparison of Amiodarone Loading Dosage in the Treatment of Postoperative Atrial Fibrillation: High Versus Standard Dose Treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1